Agnieszka NOWAK NOSZCZYK, Urszula PASLAWSKA, Alicja CEPIEL, Maciej STASZCZYK, Adrian JANISZEWSKI, Jozef NICPON

24-hour holter monitoring and troponin I level in boxers with arrhythmogenic right ventricular cardiomyopathy

Aritmojenik sağ ventrikül kardiyomiyopatisi (ARVC) azalmış penetrasyon ile otozomal dominant geçişe sahip bir hastalık olarak tanımlanır, köpeklerde 2 ve 8 yaş arasında görülür. Boxerlar ARVC yatkındırlar. ARVC semptomları bayılma , taşikardi atakları - özellikle ventriküler taşikardi ve ani kardiyak ölümdür. Bu çalışmanın amacı, aritmojenik sağ ventrikül kardiyomiyopatili Boxerlarda 24 saatlik Holter monitorizasyonunun ve tedavinin monitorize edilmesinde Troponin I düzeyinin yararlılıklarını değerlendirmektir. Antiaritmik tedavinin (metoprolol prolongatum, sotalol veya amiodaron) başlatılmasından sonra her 3 ayda bir Holter monitorizasyonu ve cTnI plazma konsantrasyonu uygulandı. 24 saatlik süreçte cTn1 düzeyi ile VPC sayısı arasında önemli bir korelasyon vardı. cTnI düzeyi ile VT görülmesi arasında hiçbir korelasyon bulunamadı. Sunulan sonuçlar ARVCli olan köpeklerde antiaritmik tedavisinin etkinliğini değerlendirmede cTnIin kullanılabilirliğini göstermektedir.

Aritmojenik sağ ventrikül kardiyomiyopatili boxerlarda 24 saatlik holter monitorizasyon ve troponin I seviyesi

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is described as a disease that has an autosomal dominant trait with reduced penetrance, that appears in dogs between two and eight years of age. Boxers are predisposed to ARVC. Some of the symptoms of ARVC are fainting, attacks of tachycardia - especially vetnricular tachycardia and sudden cardiac death. The aim of the study was to estimate the usefulness of 24-h Holter monitoring and the level of troponin I (cTnl) in examining the treatment of Boxers with ARVC. 24-h Holter monitoring and plasma concentrations of cTnI were carried out every three months after introducing anti-arrhythmic treatment (metoprolol prolongatum, sotalol or amiodaron). There was a significant correlation between the number of ventricular premature complexes (VPC) over a 24-h period and the level of cTnl. No correlation was found between the appearance of monitoring ventricular tachycardia (VT) and the level of cTnl. The presented results show the possibility to use cTnl to evaluate the efficacy of anti-arrhythmia treatment in dogs with ARVC.

PDF

___

1. Thiene G, Corrado D, Basso C: Arrythmogenic right ventricular cardio-myopathy. Orphanet J Rare Dis, 2, 45, 2007.
2. Basso C, Fox PR, Meurs KM, Towbin JA, Spier AW, Calabrese F, Maron BJ, Thiene G: Arrythmogenic right ventricular cardiomyopathy causing sudden cardiac death in boxer dogs: A new animal model of human disease. Circulation, 109, 1180-1185, 2008.
3. Baumwart RD, Meurs KM: Assessment of plasma brain natriuretic peptide concentration in Boxers with arrhythmogenic right ventricular cardiomyopaty. Am J Vet Res, 66, 2086-2089, 2005.
4. Corrado D, Thiene G: Arrythmogenic right ventricular cardiomyopathy/dysplasia: Clinical impact of molecular genetic studies. Circulation, 113, 1634-1637, 2008.
5. Hyun C, Filippich LJ: Molecular genetics of sudden cardiac death in small animals - A reviev. Vet J, 171, 39-50, 2006.
6. Meurs KM, Mauceli E, Lahmers S, Acland GM, White SN, Lindblad-Toh K: Genome-wide association identifies a deletion in the 3 untranslated region ofstriatin in a canine model of arrhythmogenic right ventricular cardiomyopathy. Hum Genet, 128, 315-324, 2010.
7. Fernandez del Palacio MJ, Bernal LJ, Bayon A, Bernabe A, Montes de Oca R, Seva J: Arrythmogenic right ventricular dysplasia/ cardiomyopathy in Siberian husky. J Small Anim Pract, 42, 137-142, 2001.
8. Mohr AJ, Kirberger RM: Arrhytmogenic right ventricular cardiomyopathy in a dog. J S Afr Vet Assoc, 71, 125-130, 2000.
9. Santilli RA, Bontempi LV, Perego M, Fornai L, Basso C: Outflow tract segmental arrhythmogenic right ventricular cardiomyopathy in an English Bulldog. J Vet Cardiol, 11, 47-51, 2009.
10. Nakao S, Hirakawa A, Yamamoto S, Kobayashi M, Machida N: Pathological features of arrhythmogenic right ventricular cardiomyopathy in middle-aged dogs. J Vet Med Sci, 73, 1031-1036, 2011.
11. Oxford EM, Danko CG, Kornreich BG, Maass K, Hemsley SA, Raskolnikov D, Fox PR, Delmar M, Moïse NS: Ultrastructural changes in cardiac myocytes from Boxer dogs with arrhythmogenic right ventricular cardiomyopathy. J Vet Cardiol, 13 (2): 101-113. 2011.
12. Meurs KM, Spier AW, Wright NA, Hamlin RL: Use of ambulatory electrocardiography for detection of ventricular premature complexes in healthy dogs. J Am Vet Med Assoc, 218, 1291-1292, 2001.
13. Oyama MA, Sisson DD, Solter PF: Prospective screening for occult cardiomyopathy in dogs by measurement of plasma atrial natriuretic peptide, B-type natriuretic peptide, and cardiac troponin-I concentrations. Am J Vet Res 68, 42-47, 2007.
14. Noszczyk-Nowak A, Nowak M: Arrytmogenic right ventricle dysplasia in boxer dog. A case report. Bull Vet Inst Pulawy, 53, 541-545, 2009.
15. Mallat Z, Tedgui A, Fontaliran F, Frank R, Durigon M, Fontaine G: Evidence of apoptosis in arrhythmogenic right ventricular dysplasia. N Engl J Med 335, 1224-1226, 1996.
16. Spier AW, Meurs KM: Evaluation of spontaneous variability in the frequency of ventricular arrhythmias in Boxer with arrhythmogenic right ventricular cardiomiopathy. J Am Vet Med Assoc, 224, 538-541, 2004.
17. Baumwart RD, Orvalho J, Meurs KM: Evaluation of serum cardiac troponin I concentration in Boxers with arrhythmogenic right ventricular cardiomyopathy. Am J Vet Res, 68, 524-528, 2007.
18. Wegner J, Cohen MH, ODonnell M, Pauliks LB: Angina pectoris with troponin increase in arrhythmogenic right ventricle dysplasia: Case article and review of the literature. Pediatr Cardiol. 33, 659-662, 2012.
19. Kostis WJ, Tedford RJ, Miller DL, Schulman SP, Tomaselli GF: Troponin- I elevation in a young man with arrhythmogenic right ventricle dysplasia/cardiomyopathy. J Interv Card Electrophysiol, 22, 49-53, 2008.
20. Patrianakos AP, Protonotarios N, Nyktari E, Pagonidis K, Tsatsopoulou A, Parthenakis FI, Vardas PE: Arrhythmogenic right ventricular cardiomyopathy/dysplasia and troponin release. Myocarditis or the hot phase of the disease. Int J Cardiol, 157, e26-e28, 2012.
21. Yao Y, Zhang S, He DS, Zhang K, Hua W, Chu J, Pu J, Chen K, Wang F, Chen X: Radiofrequency ablation of the ventricular tachycardia with arrhythmogenic right ventricular cardiomyopathy using non-contact mapping. Pacing Clin Electrophysiol, 30, 526-533, 2007.
22. Nelson OL, Lahmers S, Schneider T, Thompson P: The use of an implantable defibrillator in Boxer Dog to control clinical sings of arrhythmogenic right ventricular cardiomyopathy. J Vet Intern Med, 20, 1232-1237, 2006.
23. Fabritz L, Fortmüller L, Yu TY, Paul M, Kirchhof P: Can preload-reducing therapy prevent disease progression in arrhythmogenic right ventricular cardiomyopathy? Experimental evidence and concept for a clinical trial. Prog Biophys Mol Bio, 110, 340-346, 2012.
24. Marcus FI, Abidov A: Arrhythmogenic right ventricular cardiomyopathy 2012: Diagnostic challenges and treatment. J Cardiovasc Electrophysiol, 23, 1149-1153, 2012.